ReviewBiologics : targets & therapy2016

Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab.

Jill Mv Petkau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.